Clovis Oncology adds former Pfizer VP to board
BOULDER — Clovis Oncology (NYSE: CLVS) is increasing the number of directors on its board from 10 to 11 and filling that vacancy with Dr. Ronit Simantov, the company announced Monday in a news release.
Simantov is the chief medical officer at the cell-therapy company Gamida Cell Ltd. She had previously served as vice president for oncology global medical affairs at Pfizer Inc, with other experience at OSI Pharmaceuticals, CuraGen Corporation and Bayer HealthCare Pharmaceuticals.
Simantov will receive $55,000 in annual cash retainers for her role on the board. She will also receive a one-time option to purchase 83,212 shares of Clovis Oncology stock.
SPONSORED CONTENT
Federal District Court Rules Corporate Transparency Act Unconstitutional . . . But Most Small Businesses Must Still Comply
Lyons Gaddis Real Estate and Business Attorney Cameron Grant shares important details of the Corporate Transparency Act (CTA).
© 2021 BizWest Media LLC
BOULDER — Clovis Oncology (NYSE: CLVS) is increasing the number of directors on its board from 10 to 11 and filling that vacancy with Dr. Ronit Simantov, the company announced Monday in a news release.
Simantov is the chief medical officer at the cell-therapy company Gamida Cell Ltd. She had previously served as vice president for oncology global medical affairs at Pfizer Inc, with other experience at OSI Pharmaceuticals, CuraGen Corporation and Bayer HealthCare Pharmaceuticals.
Simantov will receive $55,000 in annual cash retainers for her role on the board. She will also receive a one-time option to purchase 83,212 shares of Clovis…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!